This trial is comparing the safety and efficacy of VRd followed by an investigational CAR-T cell therapy versus VRd and Rd in participants with newly diagnosed multiple myeloma.
SparkCures ID | 1182 |
---|---|
Trial Phase | Phase 3 |
Enrollment | 743 Patients |
Treatments | |
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Janssen Research & Development LLC to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors